Rationale
In patients with symptomatic asthma receiving ICS or ICS +LABA, Phase III studies have demonstrated improved lung function with tiotropium Respimat®, a once-daily long-acting anticholinergic bronchodilator. The efficacy of some treatments (eg ICS and omalizumab), appears higher in T H 2-high phenotypes, but no specific treatments are available that work equally well in both T H 2-high and T H 2-low phenotypes. We explored whether T H 2 biomarker status influenced responses to tiotropium in patients with moderate symptomatic asthma.
Methods
In two replicate Phase III, randomized, double-blind, placebo-controlled, parallel-group trials (NCT01172808/ NCT01172821), patients with moderate symptomatic asthma, using medium-dose ICS (400-800 µg budesonide equivalent), were administered once-daily tiotropium Respimat ® 5 µg or 2.5 µg, placebo, or salmeterol (active comparator without inferential analysis). Co-primary endpoints included peak and trough FEV 1 response (difference from baseline) at 24 weeks. Pre-planned analyses (pooled population) were performed in T H 2-high and T H 2-low subgroups defined at baseline as total serum IgE ≤ or >430 µg/L) or blood eosinophils ≤ or >0.6×10 9 /L.
Results
Of 1545 patients in the full analysis set who received tiotropium or placebo, 915/1455 were reported with IgE >430 µg/L and 300/1461 with an eosinophil count of >0.6×10 9 /L. Peak FEV 1 improved with tiotropium versus placebo, independent of IgE (p<0.0001 both doses) and eosinophil count (p<0.0001 both doses). Trough FEV 1 also improved with tiotropium versus placebo, irrespective of IgE (p<0.0001 both doses) and eosinophil count (p<0.005 both doses).
Conclusions
Once-daily tiotropium Respimat ® as add-on to ICS reduces airflow obstruction in patients with moderate symptomatic asthma, independent of T H 2 phenotype, and thus may potentially provide an important therapeutic option.
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